Deutsche Bank boosted their price target on shares of Allergan (NYSE: AGN)
A number of other firms have also recently commented on AGN. Analysts at TheStreet reiterated a ?buy? rating on shares of Allergan in a research note to investors on Thursday, December 27th. Separately, analysts at Leerink Swann reiterated an ?outperform? rating on shares of Allergan in a research note to investors on Tuesday, December 18th. Finally, analysts at Credit Agricole reiterated an ?outperform? rating on shares of Allergan in a research note to investors on Monday, December 10th. They now have a $103.00 price target on the stock.
Nineteen investment analysts have rated the stock with a buy rating, two have issued an overweight rating, and eight have assigned a hold rating to the company?s stock. Allergan currently has a consensus rating of ?overweight? and a consensus target price of $103.67.
Shares of Allergan remained flat at $103.19 during during mid-day trading trading on Monday. Allergan has a 52 week low of $81.28 and a 52 week high of $104.13. The stock?s 50-day moving average is currently $94.12. The company has a market cap of $31.009 billion and a P/E ratio of 30.16.
Allergan last released its earnings data on Tuesday, October 30th. The company reported $1.06 earnings per share for the quarter, beating the analysts? consensus estimate of $1.04 by $0.02. The company had revenue of $1.39 billion for the quarter, compared to the consensus estimate of $1.43 billion. Allergan?s revenue was up 6.4% compared to the same quarter last year. Allergan has set its Q4 guidance at $1.18-1.20 EPS. Analysts expect that Allergan will post $4.19 EPS for the current fiscal year.
Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.